IP Library Granted Patent US 10,844,069
Granted Patent B2
US 10,844,069 · App. 16/559,841 · Granted Nov 24, 2020

Pyrrolotriazine compounds as TAM inhibitors

Inventors: Yun-Long Li (Chadds Ford, PA); Xiaozhao Wang (Mt. Laurel, NJ); Chunhong He (Boothwyn, PA)
Assignee: Incyte Corporation
C07D487/04A61K31/53A61P35/00C07D403/04C07D403/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,844,069
App. No.
16/559,841
Granted
Nov 24, 2020
Kind
B2
Abstract

This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

Claims (19)

1. A method for treating a cancer in a patient, said method comprising: administering to the patient a therapeutically effective amount of a compound which is N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from lung cancer, prostate cancer, colon cancer, breast cancer, melanoma, renal cell carcinoma, gastric cancer, rhabdomyosarcoma, glioblastoma, endometrial cancer, ovarian cancer, Kaposi sarcoma, esophageal cancer, pancreatic cancer, thyroid cancer, osteosarcoma, and hepatocellular cancer.

2. The method of claim 1 , wherein the compound is N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo [1,2-j] [1, 2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

3. The method of claim 1 , wherein the cancer is lung cancer.

4. The method of claim 1 , wherein the cancer is prostate cancer.

5. The method of claim 1 , wherein the cancer is colon cancer.

6. The method of claim 1 , wherein the cancer is breast cancer.

7. The method of claim 1 , wherein the cancer is melanoma.

8. The method of claim 1 , wherein the cancer is renal cell carcinoma.

9. The method of claim 1 , wherein the cancer is gastric cancer.

10. The method of claim 1 , wherein the cancer is rhabdomyosarcoma.

11. The method of claim 1 , wherein the cancer is glioblastoma.

12. The method of claim 1 , wherein the cancer is endometrial cancer.

13. The method of claim 1 , wherein the cancer is ovarian cancer.

14. The method of claim 1 , wherein the cancer is Kaposi sarcoma.

15. The method of claim 1 , wherein the cancer is esophageal cancer.

16. The method of claim 1 , wherein the cancer is pancreatic cancer.

17. The method of claim 1 , wherein the cancer is thyroid cancer.

18. The method of claim 1 , wherein the cancer is osteosarcoma.

19. The method of claim 1 , wherein the cancer is hepatocellular cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2019
From: LI, YUN-LONG; WANG, XIAOZHAO; BARBOSA, JOSEPH; BURNS, DAVID M.; FENG, HAO; GLENN, JOSEPH; HE, CHUNHONG; HUANG, TAISHENG; MEI, SONG; ZHUO, JINCONG
To: INCYTE CORPORATION
Reel/Frame 050511/0425 →
Continuity (6)
Continuation 15971017 · May 4, 2018
Continuation 15469975 · Mar 27, 2017
Provisional Application 62438750 · Dec 23, 2016
Provisional Application 62362934 · Jul 15, 2016
Provisional Application 62314066 · Mar 28, 2016
Related Publication 20200131185A1 · Apr 30, 2020
Cited By (4)
US 12,187,730 US 12,214,036 US 12,318,389 US 12,415,809